These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 1801544

  • 1. Selegiline hydrochloride and cognition.
    Lees AJ.
    Acta Neurol Scand Suppl; 1991; 136():91-4. PubMed ID: 1801544
    [Abstract] [Full Text] [Related]

  • 2. Selegiline and cognitive function in Parkinson's disease.
    Hietanen MH.
    Acta Neurol Scand; 1991 Nov; 84(5):407-10. PubMed ID: 1776388
    [Abstract] [Full Text] [Related]

  • 3. Effect of selegiline on cognitive functions in Parkinson's disease.
    Dixit SN, Behari M, Ahuja GK.
    J Assoc Physicians India; 1999 Aug; 47(8):784-6. PubMed ID: 10778622
    [Abstract] [Full Text] [Related]

  • 4. Therapy with l-deprenyl (selegiline) and relation to abuse liability.
    Schneider LS, Tariot PN, Goldstein B.
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):750-6. PubMed ID: 7995017
    [Abstract] [Full Text] [Related]

  • 5. Effects of L-deprenyl on parkinsonian bradyphrenia.
    Eatough VM, Kempster PA, Frankel JP, Curry SH, Rogers D, Lees AJ, Stern GM.
    Adv Neurol; 1990 Dec; 53():441-3. PubMed ID: 2122651
    [No Abstract] [Full Text] [Related]

  • 6. Object alternation and orbitofrontal system dysfunction in Alzheimer's and Parkinson's disease.
    Freedman M.
    Brain Cogn; 1990 Nov; 14(2):134-43. PubMed ID: 2285509
    [Abstract] [Full Text] [Related]

  • 7. Selegiline, fluoxetine, and depression in Parkinson's disease.
    Garcia-Monco JC, Padierna A, Gomez Beldarrain M.
    Mov Disord; 1995 May; 10(3):352. PubMed ID: 7651457
    [No Abstract] [Full Text] [Related]

  • 8. Cognitive impairments in different stages of Parkinson's disease.
    Starkstein SE, Bolduc PL, Preziosi TJ, Robinson RG.
    J Neuropsychiatry Clin Neurosci; 1989 May; 1(3):243-8. PubMed ID: 2521068
    [Abstract] [Full Text] [Related]

  • 9. Parkinsonian patients without dementia or depression do not suffer from bradyphrenia as indexed by performance in mental rotation tasks with and without advance information.
    Duncombe ME, Bradshaw JL, Iansek R, Phillips JG.
    Neuropsychologia; 1994 Nov; 32(11):1383-96. PubMed ID: 7877746
    [Abstract] [Full Text] [Related]

  • 10. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment.
    Imamura K, Okayasu N, Nagatsu T.
    Acta Neurol Scand; 2011 Jul; 124(1):28-39. PubMed ID: 20880269
    [Abstract] [Full Text] [Related]

  • 11. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I.
    Eur Neurol; 1992 Jul; 32 Suppl 1():46-53. PubMed ID: 1425820
    [Abstract] [Full Text] [Related]

  • 12. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.
    Dalrymple-Alford JC, Jamieson CF, Donaldson IM.
    Clin Neuropharmacol; 1995 Aug; 18(4):348-59. PubMed ID: 8665548
    [Abstract] [Full Text] [Related]

  • 13. Effects of depression and Parkinson's disease on cognitive functioning.
    Norman S, Tröster AI, Fields JA, Brooks R.
    J Neuropsychiatry Clin Neurosci; 2002 Aug; 14(1):31-6. PubMed ID: 11884652
    [Abstract] [Full Text] [Related]

  • 14. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
    Allain H, Pollak P, Neukirch HC.
    Mov Disord; 1993 Aug; 8 Suppl 1():S36-40. PubMed ID: 8302306
    [Abstract] [Full Text] [Related]

  • 15. Selegiline and manic behavior in Parkinson's disease.
    Kurlan R, Dimitsopulos T.
    Arch Neurol; 1992 Dec; 49(12):1231. PubMed ID: 1449399
    [No Abstract] [Full Text] [Related]

  • 16. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Acta Neurol Scand Suppl; 1991 Dec; 136():70-2. PubMed ID: 1801540
    [Abstract] [Full Text] [Related]

  • 17. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH.
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [Abstract] [Full Text] [Related]

  • 18. Fluoxetine and selegiline--lack of significant interaction.
    Waters CH.
    Can J Neurol Sci; 1994 Aug; 21(3):259-61. PubMed ID: 8000982
    [Abstract] [Full Text] [Related]

  • 19. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).
    Allain H, Cougnard J, Neukirch HC.
    Acta Neurol Scand Suppl; 1991 Aug; 136():73-8. PubMed ID: 1801541
    [Abstract] [Full Text] [Related]

  • 20. Spatial and visual learning deficits in Alzheimer's and Parkinson's disease.
    Freedman M, Oscar-Berman M.
    Brain Cogn; 1989 Sep; 11(1):114-26. PubMed ID: 2789813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.